HCW Biologics Inc
HCWB4.160USD
+0.035+0.85%
Horário de mercado （ET）Cotações atrasadas em 15 min
4.67MValor de mercado
PerdaP/L TTM
Mais detalhes de HCW Biologics Inc Empresa
HCW Biologics Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions such as long-haul COVID-19. It has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth factor-β and stimulate immune cells, targeting senescent cells and the SASP factors they secrete. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, and others.
Informações da empresa
Código da empresaHCWB
Nome da EmpresaHCW Biologics Inc
Data de listagemJul 20, 2021
CEODr. Hing C. Wong, Ph.D.
Número de funcionários36
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 20
Endereço2929 N Commerce Pkwy
CidadeMIRAMAR
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal33025
Telefone19548422024
Sitehttps://hcwbiologics.com/
Código da empresaHCWB
Data de listagemJul 20, 2021
CEODr. Hing C. Wong, Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Hing C. Wong, Ph.D.
Dr. Hing C. Wong, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
509.96K
+27.06%
Ms. Rebecca Byam
Ms. Rebecca Byam
Chief Financial Officer
Chief Financial Officer
43.01K
+24.49%
Mr. Scott T. Garrett
Mr. Scott T. Garrett
Independent Chairman of the Board
Independent Chairman of the Board
25.50K
+280.84%
Mr. Lee Flowers
Mr. Lee Flowers
Senior Vice President - Business Development
Senior Vice President - Business Development
5.72K
+20.23%
Dr. Peter Rhode, Ph.D.
Dr. Peter Rhode, Ph.D.
Chief Scientific Officer, Vice President - Clinical Operations
Chief Scientific Officer, Vice President - Clinical Operations
1.94K
--
Ms. Lisa M. Giles
Ms. Lisa M. Giles
Independent Director
Independent Director
896.00
--
Mr. Rick S. Greene
Mr. Rick S. Greene
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Hing C. Wong, Ph.D.
Dr. Hing C. Wong, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
509.96K
+27.06%
Ms. Rebecca Byam
Ms. Rebecca Byam
Chief Financial Officer
Chief Financial Officer
43.01K
+24.49%
Mr. Scott T. Garrett
Mr. Scott T. Garrett
Independent Chairman of the Board
Independent Chairman of the Board
25.50K
+280.84%
Mr. Lee Flowers
Mr. Lee Flowers
Senior Vice President - Business Development
Senior Vice President - Business Development
5.72K
+20.23%
Dr. Peter Rhode, Ph.D.
Dr. Peter Rhode, Ph.D.
Chief Scientific Officer, Vice President - Clinical Operations
Chief Scientific Officer, Vice President - Clinical Operations
1.94K
--
Ms. Lisa M. Giles
Ms. Lisa M. Giles
Independent Director
Independent Director
896.00
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sex, 1 de ago
Atualizado em: sex, 1 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Wong (Hing C)
25.87%
Byam (Rebecca)
2.18%
Garrett (Scott T)
1.29%
Avantax Planning Partners, Inc
0.35%
The Vanguard Group, Inc.
0.31%
Other
69.99%
Investidores
Investidores
Proporção
Wong (Hing C)
25.87%
Byam (Rebecca)
2.18%
Garrett (Scott T)
1.29%
Avantax Planning Partners, Inc
0.35%
The Vanguard Group, Inc.
0.31%
Other
69.99%
Tipos de investidores
Investidores
Proporção
Individual Investor
30.09%
Investment Advisor
0.92%
Investment Advisor/Hedge Fund
0.51%
Research Firm
0.02%
Other
68.46%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
40
619.84K
31.44%
+87.21K
2025Q1
40
480.61K
42.86%
-46.33K
2024Q4
37
23.10M
51.86%
+2.14M
2024Q3
33
21.13M
54.31%
+156.07K
2024Q2
33
21.19M
54.45%
+322.27K
2024Q1
34
20.93M
57.88%
+1.69M
2023Q4
33
19.30M
53.71%
+122.06K
2023Q3
33
19.17M
53.35%
-2.58K
2023Q2
33
22.70M
63.26%
-3.42M
2023Q1
32
22.37M
62.46%
-3.36M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Wong (Hing C)
509.96K
25.87%
+108.61K
+27.06%
May 16, 2025
Byam (Rebecca)
43.01K
2.18%
+8.46K
+24.49%
May 12, 2025
Garrett (Scott T)
25.50K
1.29%
+18.81K
+280.84%
May 16, 2025
Avantax Planning Partners, Inc
6.99K
0.35%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
6.08K
0.31%
+5.14K
+545.33%
Mar 31, 2025
Geode Capital Management, L.L.C.
5.92K
0.3%
+1.38K
+30.23%
Mar 31, 2025
Flowers (Lee)
5.72K
0.29%
+962.00
+20.23%
May 08, 2025
Winer (Gary M)
4.08K
0.21%
+3.65K
+858.82%
May 16, 2025
Cresset Asset Management, LLC
3.30K
0.17%
--
--
Mar 31, 2025
Greene (Rick Scott)
2.07K
0.1%
+962.00
+87.14%
May 12, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
